Breaking AI & Tech News Analyzed

The LeadA range of non-opioid medications could serve as effective alternatives to powerful opioids for pain relief in emergency departments, according to a new study from researchers at the University of California, San Francisco (UCSF).The Event DetailsThe review paper examined non-opioid medications available in emergency departments and existing medical literature to identify effective alternatives for pain management. Researchers created a targeted list of medications for specific pain conditions including abdominal pain, back pain, chest pain, fracture pain, and headache.The Data AnalysisCommon pain medications like acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen showed potential to relieve all types of pain examined. More targeted applications included:Ketamine, a common anesthetic, showing promise for chest painSerotonin norepinephrine reuptake inhibitor (SNRI) antidepressants for back painSeveral types of antipsychotics for headache and abdominal painThe Impact AnalysisThe findings address the critical need for alternatives to opioids amid the ongoing opioid crisis in the United States. While researchers emphasize that opioids still have a place in medicine, the alternatives offer important options as physicians become increasingly aware of long-term consequences of opioid use. The variation in patient response to medications, often genetic in nature, further supports the need for diverse pain management approaches.The PredictionAs understanding of the neurological connections between pain and mood continues to grow, psychotropic medications are likely to play an expanded role in pain management. Future medical practice may increasingly involve personalized pain regimens that consider both the type of pain and individual patient factors, including prior medication experiences and genetic makeup.

The Lead The United States Centers for Disease Control and Prevention (CDC) has released data showing that deaths from drug overdoses fell by nearly 14 percent in 2025, continuing a third consecutive year of decline. Drug Overdose Deaths in Decline The data released on Wednesday shows that the US saw nearly 70,000 predicted overdose deaths in 2025, down from more than 81,000 in 2024. The downward trend has been welcomed in the US, which has struggled with a devastating overdose crisis fuelled largely by synthetic opioids. The Data Analysis Overdose deaths peaked during the COVID-19 pandemic, with 110,000 recorded in 2022, a surge associated with social isolation and obstacles to accessing treatment services. Experts have attributed the decline to various factors, such as wider availability of the overdose treatment naloxone, commonly sold under the brand Narcan. The Impact Analysis Testing strips that can detect fentanyl are also more common now, and regulatory changes in China have limited access to the chemicals used to manufacture the drug. While overdose deaths declined in most US states in 2025, seven states saw increases. In Arizona, Colorado and New Mexico, overdose deaths increased by 10 percent or more. The Prediction “I’m cautiously optimistic that this represents really a fundamental change in the arc of the overdose crisis,” Brandon Marshall, a Brown University researcher who studies overdose trends, told The Associated Press news service. The administration of President Donald Trump has pointed to the decrease overall as validation of its crackdown on drug trafficking.

The End of Purdue Pharma Purdue Pharma, the manufacturer of OxyContin, is slated to be dissolved by the end of the week as a comprehensive legal settlement takes effect. This settlement resolves thousands of lawsuits filed against the company for its role in the opioid crisis, which has claimed over 900,000 lives in the US since 1999. Terms of the Settlement As part of the deal, Purdue Pharma will admit to not having an effective program to prevent its powerful painkillers from being diverted to the black market. The company will also admit to paying doctors to prescribe the drugs and providing information to encourage more opioid prescriptions. The settlement includes $8.3 billion in forfeitures, fines, and penalties, although the company will only pay $225 million to the federal government. Victims' Reactions Many victims of the opioid crisis expressed frustration with the settlement, arguing that it does not provide them with real justice. Some asked the judge to reject the negotiated sentence, stating that it does not hold individual members of the Sackler family accountable. Over 54,000 people with personal injury claims voted to accept the settlement, while about 200 rejected it. The Sackler Family's Role Members of the Sackler family, who own Purdue Pharma, will contribute up to $7 billion over 15 years to fight the opioid crisis. Most of the funds will go to government entities. The settlement also shields family members from lawsuits over opioids for those who agree to the payments. A New Era for Purdue Pharma Under the settlement, Purdue Pharma will cease to exist and be replaced by Knoa Pharma, a new company with a board appointed by states and a mission to combat the opioid crisis. Millions of internal Purdue documents will be made public, and the Sackler family has agreed not to object to having their names removed from institutions they have supported.

A federal judge is set to finalize a historic legal reckoning for Purdue Pharma, ordering the company to forfeit $225m. This penalty clears the final hurdle for a $50bn settlement that will dissolve Purdue into a public-benefit entity and force the Sackler family to pay up to $7bn over 15 years. The deal resolves thousands of lawsuits alleging the company fueled the US opioid crisis through deceptive marketing and aggressive sales tactics.Key DevelopmentsGuilty Plea & Forfeiture: Purdue Pharma pleaded guilty in November 2020 to three federal criminal charges, including failing to prevent diversion of OxyContin and paying kickbacks to doctors.Restructuring: Purdue will cease to exist and be replaced by a new company, Knoa Pharma, which will operate for the public benefit with a board appointed by state governments.Sackler Immunity: The settlement shields members of the Sackler family from future civil lawsuits related to opioids, provided they contribute to the fund.Victim Acceptance: More than 54,000 victims with personal injury claims voted to accept the settlement, though 218 voted against it.Data & Market ImpactThe settlement represents one of the largest corporate resolutions in US history, fundamentally altering the landscape of pharmaceutical liability. Key figures include:$50bn Total Settlement: The combined value of settlements by Purdue and other drugmakers, wholesalers, and pharmacies.$7bn Sackler Contribution: The maximum amount the family must pay to governments, tribes, and victims over 15 years.$1bn Legal Fees: Purdue has already paid over $1bn to law firms and professionals involved in the complex restructuring.900,000 Deaths: The crisis has been linked to approximately 900,000 deaths in the US since 1999.Why This MattersThis ruling marks a watershed moment for how corporations are held accountable for public health crises. By dissolving Purdue into a public-benefit company, the settlement creates a mechanism where the company's future profits directly fund addiction treatment and prevention programs. However, the impact is uneven; while state and local governments will receive billions to combat the epidemic, individual victims may receive significantly less than they seek, sparking ongoing debate over whether the justice system prioritizes corporate stability over individual suffering.Expert InsightThe agreement represents a strategic trade-off by the Department of Justice (DOJ). By accepting a guaranteed payout of billions rather than risking a lengthy trial that might result in a smaller or zero verdict, the government secured immediate capital to fight the overdose epidemic. The inclusion of the Sackler family's payment cap is a controversial but pragmatic move; it likely reflects the DOJ's assessment that a trial would be prohibitively expensive and time-consuming, potentially yielding no recovery at all. Furthermore, the requirement for the Sacklers to remove their names from institutions is a symbolic victory, though critics argue it does not address the moral culpability of the individuals involved.What Happens NextThe dissolution of Purdue Pharma into Knoa Pharma is expected to take effect on 1 May. The new entity will begin transferring assets and funds to the settlement trust. Over the next 15 years, the Sackler family will begin making payments to state and local governments, which are tasked with using these funds to address the opioid crisis. Despite the settlement, legal challenges from victims who rejected the deal are likely to persist, potentially leading to further litigation regarding the adequacy of the compensation and the validity of the immunity granted to the Sacklers.

New data from the National Survey on Drug Use and Health reveal that cocaine, once a hallmark of American party culture, is losing its grip: prevalence fell to 1.5% (about 4.3 million adults) in 2024, down from 5.9 million in 2017, and use among 18‑25‑year‑olds dropped from 2.1 million to 811 000.Key DevelopmentsOverall adult cocaine use: 1.5% in 2024 vs 6.7% in early 2000s.Gen Z (18‑25) consumption fell >60% between 2017 and 2024.Purity of seized cocaine rose to 88% in 2024, up from 54% in 2020.Overdose deaths involving cocaine climbed from 10,475 in 2016 to 22,174 in 2024.Alternative substances – ketamine, psychedelics, GHB, 3‑MMC and prescription stimulants – are reported as increasingly popular in club scenes.Data & Market Impact4.3 million adults reported cocaine use in the past year (2024).Supply surge from Colombia has driven purity up, potentially intensifying health risks.Mixed‑drug environment: law‑enforcement seizures now show higher rates of cocaine combined with fentanyl or other opioids, though true contamination remains low.Why This MattersThe decline reshapes several arenas:Public health: fewer users may reduce long‑term cardiovascular disease burden, but rising overdose deaths signal a dangerous shift toward polydrug use.Law‑enforcement: reduced demand could alter trafficking routes, while higher purity may incentivize dealers to diversify into more profitable synthetics.Pharmaceutical and wellness markets: growing preference for “controlled” substances like Adderall or therapeutic ketamine points to a broader wellness‑oriented drug culture.Policy: data may prompt a re‑evaluation of the “war on drugs” narrative and encourage harm‑reduction strategies targeting mixed‑drug use.Expert InsightAnalysts attribute the shift to a convergence of cultural and economic forces. Gen Z’s heightened health consciousness and aversion to the “brash” image of cocaine drive demand toward substances perceived as safer or more therapeutic, such as ketamine, which is marketed for its antidepressant properties. At the same time, the fear of fentanyl contamination—whether statistically rare or not—creates a risk‑averse environment. Supply‑side dynamics, including record‑high Colombian output and a jump in cocaine purity to 88%, make the drug more potent, raising the stakes for accidental overdose when combined with opioids. The result is a fragmented market where cocaine is no longer the sole “star” but one component of a broader, messier drug ecosystem.What Happens NextContinued decline in pure‑cocaine use, especially among younger cohorts, is likely as alternative psych‑delics gain cultural cachet.Regulators may increase monitoring of ketamine and novel stimulants, potentially introducing new scheduling or prescription‑only frameworks.Overdose prevention efforts will need to address mixed‑drug toxicity, emphasizing testing kits and education about fentanyl‑laced supplies.Drug‑trafficking organizations could pivot toward higher‑margin synthetics, reshaping the illicit market’s geography and profit structures.

Euphoria's third season has been a long-awaited return, but unfortunately, it's absolutely not worth the wait. The show's creator, Sam Levinson, has taken a darker and more desperate approach, focusing on the characters' bleak lives and struggles with sex work, drugs, and trauma.The season picks up five years after the end of season two, with recovering addict Rue (Zendaya) drawn into the world of drug dealer Laurie (Martha Kelly). Her life as a mule between Mexico and the US is depicted in gritty and intense cinematic sequences, drawing on westerns and blaxploitation.Meanwhile, Cassie (Sydney Sweeney) is on the cusp of trad wifedom with toxic jock Nate (Jacob Elordi), but their relationship is marred by Nate's crumbling business and Cassie's OnlyFans content. The show's handling of her cam girl ambitions feels bafflingly dated and voyeuristic.The performances are mostly good, with standout performances from Zendaya, Sweeney, and Adewale Akinnuoye-Agbaje. However, the show's grim and humorless tone makes it feel like a chore to watch.Levinson's approach to exploring the devastating impact of synthetic opioids on ordinary Americans feels heavy-handed and desperate. The show's focus on brainrot bimbo-ism and male perversion also detracts from its once unapologetically queer heart.Overall, Euphoria season three is a disappointing and grubby addition to the series, feeling like a contractual obligation rather than a passion project.

Recent CDC data reveal a dramatic 1,200% increase in kratom‑related poisonings across the United States over the last ten years, with the most pronounced surge recorded in 2025. Researchers link this rise to the growing presence of 7‑hydroxymitragynine (7‑OH), a synthetically produced compound that mimics kratom’s effects but carries opioid‑like risks. Walter Prozialeck, pharmacology professor at Midwestern University, said the trend was expected, noting that the synthetic alkaloid has entered the market through energy drinks and other products since 2024. Christopher McCurdy of the University of Florida warned that marketing 7‑OH as “enhanced kratom” blurs the line for consumers, turning poison‑control calls into a conflated metric for both natural and synthetic products. By contrast, natural kratom (Mitragyna speciosa)—a Southeast Asian plant used for centuries as a pain reliever—has demonstrated a relatively favorable safety profile in animal and human studies. A 2018 statement from then‑HHS Secretary Brett Giroir rejected the DEA’s push to schedule kratom as a Schedule I substance, citing insufficient evidence of harm. Despite the scientific distinction, several states have moved to implement or propose blanket bans on all kratom products, prompting concern from clinicians and patient advocates. A recent user survey indicated that about 50% of respondents rely on kratom for chronic pain, while roughly 40% use it during addiction recovery. Personal testimonies underscore the plant’s therapeutic role. Jeff Maslan, a 68‑year‑old Californian with severe osteoarthritis, credits kratom with easing opioid withdrawal after multiple surgeries. Similarly, “Steven,” a disabled California resident, describes how kratom eliminated unbearable oxycodone withdrawal symptoms without producing the euphoric “warm fuzzy” feeling typical of opioids. Researchers emphasize that 7‑OH carries genuine opioid hazards, including addiction, severe withdrawal, and respiratory depression that can lead to fatal overdose. In animal models, 7‑OH demonstrated the same respiratory‑depression risk as classic opioids, whereas kratom’s primary alkaloid did not. Prozialeck and colleagues explain that kratom’s pharmacology is more nuanced: it partially activates opioid receptors while also engaging adrenergic and serotonin pathways, resembling a hybrid of a weak opioid and an SNRI‑type antidepressant. This multimodal action likely accounts for its lower euphoric potential and the reported boost in energy among users. Nevertheless, experts caution that kratom is not without risk. Fatal poisonings often involve co‑ingestion of potent opioids such as fentanyl, suggesting that some users may cycle between kratom and stronger substances, raising overdose danger due to reduced opioid tolerance. Additionally, heavy‑metal contamination has been detected in certain kratom batches, though the source—soil, processing, or storage—remains unclear. Given these complexities, the consensus among scholars like Austin Zamarripa (Johns Hopkins) is that natural kratom should remain accessible, while concentrated 7‑OH products merit stricter regulation. “These products may offer meaningful benefits to some individuals, and those benefits could be lost if access is restricted too broadly,” Zamarripa said, urging a differentiated policy approach. As the debate unfolds, patients like Steven worry that a sweeping ban would ignore the nuanced safety profile of the plant. “There’s corn on the cob, there’s high‑fructose corn syrup, there’s whiskey— all derived from corn but fundamentally different,” he remarked, highlighting the need for targeted, evidence‑based regulation rather than a one‑size‑fits‑all prohibition.